Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 37 studies | 35% ± 16% | |
fibroblast | 24 studies | 33% ± 12% | |
astrocyte | 19 studies | 43% ± 17% | |
smooth muscle cell | 18 studies | 29% ± 10% | |
pericyte | 16 studies | 28% ± 10% | |
oligodendrocyte | 16 studies | 68% ± 17% | |
endothelial cell of lymphatic vessel | 12 studies | 34% ± 15% | |
macrophage | 12 studies | 34% ± 18% | |
oligodendrocyte precursor cell | 12 studies | 37% ± 16% | |
capillary endothelial cell | 12 studies | 25% ± 10% | |
microglial cell | 12 studies | 41% ± 15% | |
plasma cell | 10 studies | 34% ± 14% | |
glutamatergic neuron | 10 studies | 67% ± 23% | |
ciliated cell | 10 studies | 31% ± 13% | |
adipocyte | 9 studies | 53% ± 18% | |
GABAergic neuron | 8 studies | 44% ± 19% | |
basal cell | 8 studies | 30% ± 18% | |
myofibroblast cell | 8 studies | 29% ± 12% | |
retinal ganglion cell | 7 studies | 63% ± 22% | |
naive B cell | 7 studies | 22% ± 4% | |
epithelial cell | 7 studies | 40% ± 16% | |
retinal cone cell | 7 studies | 44% ± 14% | |
retinal rod cell | 7 studies | 51% ± 19% | |
B cell | 7 studies | 26% ± 10% | |
mast cell | 7 studies | 25% ± 8% | |
vein endothelial cell | 7 studies | 33% ± 23% | |
type I pneumocyte | 7 studies | 34% ± 13% | |
interneuron | 6 studies | 29% ± 12% | |
connective tissue cell | 6 studies | 24% ± 7% | |
club cell | 6 studies | 32% ± 12% | |
dendritic cell | 6 studies | 22% ± 4% | |
endothelial cell of artery | 6 studies | 20% ± 3% | |
Mueller cell | 6 studies | 43% ± 13% | |
endothelial cell of vascular tree | 6 studies | 34% ± 18% | |
type II pneumocyte | 6 studies | 32% ± 8% | |
retina horizontal cell | 5 studies | 35% ± 13% | |
cardiac muscle cell | 5 studies | 51% ± 16% | |
T cell | 5 studies | 26% ± 8% | |
cholangiocyte | 4 studies | 55% ± 26% | |
hepatocyte | 4 studies | 75% ± 21% | |
neuron | 4 studies | 62% ± 18% | |
glial cell | 4 studies | 35% ± 10% | |
granule cell | 4 studies | 54% ± 19% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 20% ± 4% | |
lymphocyte | 4 studies | 31% ± 10% | |
myeloid cell | 4 studies | 30% ± 7% | |
muscle cell | 4 studies | 36% ± 18% | |
monocyte | 4 studies | 29% ± 4% | |
natural killer cell | 4 studies | 21% ± 3% | |
goblet cell | 4 studies | 39% ± 26% | |
hepatic stellate cell | 3 studies | 53% ± 18% | |
memory B cell | 3 studies | 15% ± 0% | |
precursor B cell | 3 studies | 22% ± 3% | |
retinal pigment epithelial cell | 3 studies | 39% ± 26% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 19% ± 1% | |
mesothelial cell | 3 studies | 37% ± 9% | |
mucosal invariant T cell | 3 studies | 20% ± 4% | |
plasmablast | 3 studies | 33% ± 9% | |
abnormal cell | 3 studies | 34% ± 17% | |
ependymal cell | 3 studies | 49% ± 20% | |
adventitial cell | 3 studies | 27% ± 6% | |
alveolar macrophage | 3 studies | 25% ± 3% | |
chondrocyte | 3 studies | 30% ± 9% | |
respiratory goblet cell | 3 studies | 37% ± 16% | |
Schwann cell | 3 studies | 40% ± 17% | |
melanocyte | 3 studies | 31% ± 17% | |
brush cell | 3 studies | 26% ± 7% | |
kidney loop of Henle epithelial cell | 3 studies | 33% ± 10% | |
renal alpha-intercalated cell | 3 studies | 28% ± 10% | |
mucus secreting cell | 3 studies | 36% ± 10% | |
myoepithelial cell | 3 studies | 42% ± 19% | |
CD8-positive, alpha-beta T cell | 3 studies | 18% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 7205.98 | 180 / 180 | 100% | 40.22 | 430 / 430 |
pancreas | 100% | 3833.90 | 328 / 328 | 100% | 56.64 | 178 / 178 |
brain | 100% | 6601.98 | 2640 / 2642 | 99% | 46.52 | 701 / 705 |
esophagus | 100% | 4475.09 | 1439 / 1445 | 99% | 77.40 | 182 / 183 |
thymus | 100% | 4543.94 | 653 / 653 | 99% | 42.93 | 599 / 605 |
adrenal gland | 100% | 7918.64 | 258 / 258 | 99% | 65.50 | 227 / 230 |
lung | 100% | 5345.64 | 577 / 578 | 99% | 45.48 | 1140 / 1155 |
intestine | 100% | 4999.67 | 966 / 966 | 98% | 46.70 | 519 / 527 |
bladder | 100% | 5506.62 | 21 / 21 | 98% | 39.66 | 496 / 504 |
breast | 100% | 6275.29 | 459 / 459 | 98% | 55.00 | 1100 / 1118 |
stomach | 100% | 3046.06 | 358 / 359 | 99% | 57.61 | 282 / 286 |
kidney | 100% | 3220.17 | 89 / 89 | 98% | 60.66 | 883 / 901 |
uterus | 100% | 5049.75 | 170 / 170 | 94% | 35.00 | 433 / 459 |
liver | 100% | 5277.38 | 226 / 226 | 92% | 30.75 | 372 / 406 |
prostate | 100% | 4518.94 | 245 / 245 | 91% | 28.43 | 459 / 502 |
skin | 99% | 3725.01 | 1796 / 1809 | 92% | 63.75 | 432 / 472 |
adipose | 100% | 6482.04 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 6737.80 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 4822.78 | 803 / 803 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 9.76 | 1 / 1 |
heart | 97% | 3527.92 | 839 / 861 | 0% | 0 | 0 / 0 |
spleen | 97% | 1879.52 | 234 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 32.30 | 40 / 45 |
eye | 0% | 0 | 0 / 0 | 74% | 22.95 | 59 / 80 |
lymph node | 0% | 0 | 0 / 0 | 69% | 10.05 | 20 / 29 |
peripheral blood | 22% | 347.12 | 208 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043484 | Biological process | regulation of RNA splicing |
GO_0008380 | Biological process | RNA splicing |
GO_0006397 | Biological process | mRNA processing |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | MBNL2 |
Protein name | Muscleblind-like protein 2 (Muscleblind-like protein 1) (Muscleblind-like protein-like) (Muscleblind-like protein-like 39) Muscleblind like splicing regulator 2 (Muscleblind-like 2 (Drosophila), isoform CRA_b) (Zinc finger protein) Muscleblind-like 2 (Drosophila), isoform CRA_a (cDNA FLJ76890, highly similar to Homo sapiens muscleblind-like 2 (Drosophila) (MBNL2), transcript variant 3, mRNA) (cDNA, FLJ79493, highly similar to Homo sapiens muscleblind-like 2 (Drosophila) (MBNL2), transcript variant 3, mRNA) MBNL2 protein Muscleblind like splicing regulator 2 |
Synonyms | MBLL MBLL39 hCG_27557 MLP1 |
Description | FUNCTION: Mediates pre-mRNA alternative splicing regulation. Acts either as activator or repressor of splicing on specific pre-mRNA targets. Inhibits cardiac troponin-T (TNNT2) pre-mRNA exon inclusion but induces insulin receptor (IR) pre-mRNA exon inclusion in muscle. Antagonizes the alternative splicing activity pattern of CELF proteins. RNA-binding protein that binds to 5'ACACCC-3' core sequence, termed zipcode, within the 3'UTR of ITGA3. Binds to CUG triplet repeat expansion in myotonic dystrophy muscle cells by sequestering the target RNAs. Together with RNA binding proteins RBPMS and RBFOX2, activates vascular smooth muscle cells alternative splicing events (By similarity). Regulates NCOR2 alternative splicing (By similarity). Seems to regulate expression and localization of ITGA3 by transporting it from the nucleus to cytoplasm at adhesion plaques. May play a role in myotonic dystrophy pathophysiology (DM). . |
Accessions | ENST00000449284.1 ENST00000397601.5 [Q5VZF2-3] A0A8I5KYZ5 A0A994J509 Q5JSC0 A0A8I5KU79 A0A7P0T9I3 ENST00000345429.10 [Q5VZF2-2] ENST00000685165.1 A0A994J506 ENST00000692685.1 ENST00000704364.1 ENST00000704373.1 A2A3S3 ENST00000376673.8 [Q5VZF2-1] ENST00000343600.9 [Q5VZF2-3] A0PJJ3 ENST00000679496.1 O95205 ENST00000469707.5 Q5VZF2 |